Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
The First Hospital of Jilin University, Changchun, Jilin, China
Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
Cleveland Clinic Florida, Weston, Florida, United States
Hospital For Special Surgery, New York, New York, United States
Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
CHRU de Nancy, Hopitaux de Brabois, Vandoeuvre Les Nancy, France
CHU Strasbourg, Strasbourg, France
Hôpital Charles Nicolle, Rouen, France
Brooke Army Medical Center, San Antonio, Texas, United States
Bezmialem Vakif University, Istanbul, Fatih, Turkey
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.